Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Public ClinicalTrials.gov record NCT00720174. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial is studying the side effects and best dose of cixutumumab given together with doxorubicin hydrochloride and to see how well they work in treating patients with unresectable, locally advanced, or metastatic soft tissue sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antibody cixutumumab together with doxorubicin hydrochloride may kill more tumor cells.
Study identification
- NCT ID
- NCT00720174
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 30 participants
Conditions and interventions
Conditions
- Adult Angiosarcoma
- Adult Desmoplastic Small Round Cell Tumor
- Adult Epithelioid Sarcoma
- Adult Extraskeletal Myxoid Chondrosarcoma
- Adult Extraskeletal Osteosarcoma
- Adult Fibrosarcoma
- Adult Leiomyosarcoma
- Adult Liposarcoma
- Adult Malignant Mesenchymoma
- Adult Malignant Peripheral Nerve Sheath Tumor
- Adult Rhabdomyosarcoma
- Adult Synovial Sarcoma
- Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone
- Childhood Angiosarcoma
- Childhood Desmoplastic Small Round Cell Tumor
- Childhood Epithelioid Sarcoma
- Childhood Fibrosarcoma
- Childhood Leiomyosarcoma
- Childhood Liposarcoma
- Childhood Malignant Mesenchymoma
- Childhood Malignant Peripheral Nerve Sheath Tumor
- Childhood Pleomorphic Rhabdomyosarcoma
- Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features
- Childhood Synovial Sarcoma
- Dermatofibrosarcoma Protuberans
- Malignant Adult Hemangiopericytoma
- Malignant Childhood Hemangiopericytoma
- Metastatic Childhood Soft Tissue Sarcoma
- Previously Treated Childhood Rhabdomyosarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Childhood Soft Tissue Sarcoma
- Stage III Adult Soft Tissue Sarcoma
- Stage IV Adult Soft Tissue Sarcoma
- Untreated Childhood Rhabdomyosarcoma
Interventions
- Cixutumumab Biological
- Doxorubicin Hydrochloride Drug
- Laboratory Biomarker Analysis Other
Biological · Drug · Other
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2008
- Primary completion
- Dec 31, 2012
- Completion
- Not listed
- Last update posted
- May 16, 2016
Started 2008
United States locations
- U.S. sites
- 13
- U.S. states
- 6
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637 | — |
| Decatur Memorial Hospital | Decatur | Illinois | 62526 | — |
| NorthShore University HealthSystem-Evanston Hospital | Evanston | Illinois | 60201 | — |
| Ingalls Memorial Hospital | Harvey | Illinois | 60426 | — |
| Joliet Oncology-Hematology Associates Limited | Joliet | Illinois | 60435 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Illinois CancerCare-Peoria | Peoria | Illinois | 61615 | — |
| Central Illinois Hematology Oncology Center | Springfield | Illinois | 62702 | — |
| Fort Wayne Medical Oncology and Hematology Inc-Parkview | Fort Wayne | Indiana | 46845 | — |
| University of Maryland/Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Mercy Hospital Saint Louis | St Louis | Missouri | 63141 | — |
| Froedtert and the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00720174, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 16, 2016 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00720174 live on ClinicalTrials.gov.